Baseline characteristics of cancer patients initiating chemotherapy
| . | . | Khorana risk score category . | ||
|---|---|---|---|---|
| . | All, n (%) . | 0: low, n (%) . | 1-2: intermediate, n (%) . | ≥3: High, n (%) . |
| Patients | 40 218 (100) | 14 250 (35.4) | 21 565 (53.6) | 4 403 (10.9) |
| Sex, female | 22 290 (55.4) | 8 338 (58.5) | 11 568 (53.6) | 2 384 (54.1) |
| Age (y), median (IQR) | 65.0 (55.0-72.0) | 63.0 (53.0-71.0) | 66.0 (57.0-73.0) | 66.0 (58.0-72.0) |
| Age <50 y | 5 711 (14.2) | 2 534 (17.8) | 2 692 (12.5) | 485 (11.0) |
| Age 50-69 y | 20 814 (51.8) | 7 503 (52.7) | 10 989 (51.0) | 2 322 (52.7) |
| Age ≥70 y | 13 693 (34.0) | 4 213 (29.6) | 7 884 (36.6) | 1 596 (36.2) |
| Khorana score | ||||
| 0 | 14 250 (35.4) | |||
| 1 | 12 856 (32.0) | |||
| 2 | 8 709 (21.7) | |||
| 3 | 3 623 (9.0) | |||
| 4 | 717 (1.8) | |||
| 5-6* | 63 (.02) | |||
| Cancer type | ||||
| Stomach | 1 250 (3.1) | 0 (0.0) | 685 (3.2) | 565 (12.8) |
| Pancreatic | 1 671 (4.2) | 0 (0.0) | 843 (3.9) | 828 (18.8) |
| Lung | 6 556 (16.3) | 0 (0.0) | 5 123 (23.8) | 1 433 (32.5) |
| Lymphoma | 3 095 (7.7) | 0 (0.0) | 2 617 (12.1) | 478 (10.9) |
| Gynecologic | 2 728 (6.8) | 0 (0.0) | 2 188 (10.1) | 540 (12.3) |
| Bladder | 767 (1.9) | 0 (0.0) | 619 (2.9) | 148 (3.4) |
| Testicular | 347 (0.9) | 0 (0.0) | 326 (1.5) | 21 (0.5) |
| Other | 23 804 (59.3) | 14 250 (100) | 9 164 (42.5) | 390 (8.9) |
| Hemoglobin level <10 g/dL or use of erythropoiesis-stimulating agent | 3 452 (8.6) | 0 (0.0) | 2 137 (9.9) | 1 315 (29.9) |
| Platelet count ≥350 × 109/L | 13 241 (32.9) | 0 (0.0) | 9 301 (43.1) | 3 940 (89.5) |
| Leukocyte count >11 × 109/L | 7 830 (19.5) | 0 (0.0) | 4 586 (21.3) | 3 244 (73.7) |
| Body mass index ≥35 kg/m2 | 470 (1.2) | 0 (0.0) | 321 (1.5) | 149 (3.4) |
| . | . | Khorana risk score category . | ||
|---|---|---|---|---|
| . | All, n (%) . | 0: low, n (%) . | 1-2: intermediate, n (%) . | ≥3: High, n (%) . |
| Patients | 40 218 (100) | 14 250 (35.4) | 21 565 (53.6) | 4 403 (10.9) |
| Sex, female | 22 290 (55.4) | 8 338 (58.5) | 11 568 (53.6) | 2 384 (54.1) |
| Age (y), median (IQR) | 65.0 (55.0-72.0) | 63.0 (53.0-71.0) | 66.0 (57.0-73.0) | 66.0 (58.0-72.0) |
| Age <50 y | 5 711 (14.2) | 2 534 (17.8) | 2 692 (12.5) | 485 (11.0) |
| Age 50-69 y | 20 814 (51.8) | 7 503 (52.7) | 10 989 (51.0) | 2 322 (52.7) |
| Age ≥70 y | 13 693 (34.0) | 4 213 (29.6) | 7 884 (36.6) | 1 596 (36.2) |
| Khorana score | ||||
| 0 | 14 250 (35.4) | |||
| 1 | 12 856 (32.0) | |||
| 2 | 8 709 (21.7) | |||
| 3 | 3 623 (9.0) | |||
| 4 | 717 (1.8) | |||
| 5-6* | 63 (.02) | |||
| Cancer type | ||||
| Stomach | 1 250 (3.1) | 0 (0.0) | 685 (3.2) | 565 (12.8) |
| Pancreatic | 1 671 (4.2) | 0 (0.0) | 843 (3.9) | 828 (18.8) |
| Lung | 6 556 (16.3) | 0 (0.0) | 5 123 (23.8) | 1 433 (32.5) |
| Lymphoma | 3 095 (7.7) | 0 (0.0) | 2 617 (12.1) | 478 (10.9) |
| Gynecologic | 2 728 (6.8) | 0 (0.0) | 2 188 (10.1) | 540 (12.3) |
| Bladder | 767 (1.9) | 0 (0.0) | 619 (2.9) | 148 (3.4) |
| Testicular | 347 (0.9) | 0 (0.0) | 326 (1.5) | 21 (0.5) |
| Other | 23 804 (59.3) | 14 250 (100) | 9 164 (42.5) | 390 (8.9) |
| Hemoglobin level <10 g/dL or use of erythropoiesis-stimulating agent | 3 452 (8.6) | 0 (0.0) | 2 137 (9.9) | 1 315 (29.9) |
| Platelet count ≥350 × 109/L | 13 241 (32.9) | 0 (0.0) | 9 301 (43.1) | 3 940 (89.5) |
| Leukocyte count >11 × 109/L | 7 830 (19.5) | 0 (0.0) | 4 586 (21.3) | 3 244 (73.7) |
| Body mass index ≥35 kg/m2 | 470 (1.2) | 0 (0.0) | 321 (1.5) | 149 (3.4) |
Percentages may not add up to 100 due to rounding.
Categories collapsed to avoid violations of data protection regulations imposed by the Danish Health Data Authority.